Markets
Illustration - Diabetes
A man injects the drug Ozempic into his stomach with a syringe to treat Type 2 diabetes (Getty Images)

Novo Nordisk cuts outlook again amid obesity drug slowdown and Pfizer bidding war

The Q3 earnings report comes at a tumultuous time for the company.

Novo Nordisk reported quarterly earnings results Wednesday that missed Wall Street estimates, as the company fights a bidding war that could determine its future in the obesity drug market.

The Danish pharmaceutical giant reported quarterly adjusted earnings per share of $0.70, compared to the $0.76 analysts had estimated, per Bloomberg-compiled estimates. It also reported $11.7 billion in sales, short of the $11.9 billion the Street had penciled in. Novo trimmed its full-year growth forecast for the fourth time this year, too, and now projects sales growth of 8% to 11% and operating profit growth of 4% to 7%, down from its previous 8% to 14% and 4% to 10% forecasts, respectively.

The earnings report comes at a tumultuous time for the company. Its bidding against Pfizer for obesity biotech company Metsera, which is working on next-generation GLP-1 drugs. This comes after its top investor shook up the board last month, accusing the previous directors of not being aggressive enough in the weight-loss drug race.

Novo was the first to bring GLP-1s to market but has seen its sales growth fade in recent quarters as it faces increased competition from Eli Lillyand telehealth companies that sell copies of its drugs, such as Hims & Hers.

Shares slumped as much as ~4% overnight, but have since rebounded to trade about 1.2% higher in the premarket at the time of writing. The stock is still down around 44% year to date.

More Markets

See all Markets
markets

Report: Boeing could unveil 500-jet order from China during Trump’s visit later this month

Shares of Boeing are up nearly 4% on Friday afternoon, following a Bloomberg report that the company could be close to finalizing a deal to sell 500 planes to China.

The deal was first reported in August and would be one of Boeing’s largest ever.

According to Bloomberg’s sources, the deal could be officially unveiled when President Trump travels to China at the end of the month. That trip could be delayed given the war in Iran. The deal, sources say, could still fall apart — similar language to when it was first reported on more than six months ago.

Boeing has been on the outside of the Chinese market, in terms of new orders, since 2019 amid escalating US-China trade tensions.

According to Bloomberg’s sources, the deal could be officially unveiled when President Trump travels to China at the end of the month. That trip could be delayed given the war in Iran. The deal, sources say, could still fall apart — similar language to when it was first reported on more than six months ago.

Boeing has been on the outside of the Chinese market, in terms of new orders, since 2019 amid escalating US-China trade tensions.

markets

Why software shares are withstanding the war jitters

The outbreak of the war in Iran has clearly rattled investors and created a few clear winners — mostly energy stocks — and losers — consumer staples, airlines, and, well, more or else everything else.

But there is one interesting outlier to that Manichaean market dynamic.

Software shares — often the same companies that the market was giving up for dead just a few weeks ago due to overexpectations of an AI-driven disruption — have been holding up remarkably well.

These companies, including Intuit, ServiceNow, Datadog, Snowflake, IBM, Workday, and Oracle, have actually had a pretty decent run since the war started with a combined US-Israeli attack on Iran last weekend.

A new note from RBC Capital’s Rishi Jaluria suggests this isn’t just a fluke. Looking at the performance of software stocks during periods of geopolitical stress and market volatility over the last 10 and 25 years, his team found that software shares appear fairly well insulated when these broader shocks hit. RBC wrote:

“The defensive nature of SaaS models and the mission-critical nature of many core software systems at the enterprise level (e.g., in the absence of mass layoffs that may create seat-based headwinds, geopolitical uncertainty and/or market volatility typically will not cause an enterprise CIO to consider ripping out their ERP, CRM, Cyber systems, etc.”

I briefly got Jaluria on the phone yesterday, and he explained a bit more about why he thinks investors might see software as a decent place to hide out from the current chaos.

“With everything in the Middle East, you have to think about not just oil and gas input prices but also supply chains,” he said. “With software, you’re not really thinking about that.”

In other words, there is no equivalent of a closure of the Strait of Hormuz that software investors have to worry about.

Others suggested that the near-term profitability of these giant software companies — aside from concerns about potential long-term disruption from AI — may look different in the face of the economic uncertainty that seems to be growing with the war, especially after a sell-off that has left them relatively attractively valued.

Mark Moerdler, who covers software stocks for Bernstein Research, says that while the AI worries are clearly real, software companies continue to be highly productive cash cows.

“Everyone is afraid that AI is a massive disruptor, and all these articles you read talk about AI as massive disruptor or the world is ending or whatever,” he said. “You don’t see it in the fundamental numbers of the companies I cover. They are delivering GAAP profits, free cash flow, and they’re good investment ideas.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.